Refine by
Laboratory Costs Articles & Analysis
10 news found
Ended the quarter with $47.2 million in cash and investments – expected to fund operations through the end of 2024, including release of topline SAVVE pivotal trial data IRVINE, CA / August 3, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today provided a ...
Ended the quarter with $51.3 million in cash – expected to fund operations through the end of 2024 including release of topline pivotal trial data Ongoing advancement of SAVVE U.S pivotal trial with 20 sites available to enroll patients Progress on development of second device for the treatment of venous disease expected to be unveiled in mid-2022 IRVINE, CA / May 2, 2022 / enVVeno ...
Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial Data Nine (9) VenoValve Surgeries Successfully Completed and 16 Clinical Sites Currently Active in Ongoing SAVVE U.S Pivotal Trial Continued Advancement in Development of Second Device for the Treatment of Venous Disease Expected To Be Unveiled in Mid-2022 ...
The first-generation smart insole PODOSmart® system was first introduced in 2019 as a new tool for gait analysis against high-cost laboratory-based equipment. The PODOSmart®?system measures walking profile and gait variables in real-life conditions. ...
The study also concluded that because PODOSmart® is a portable gait analysis tool with an affordable cost it can be a useful new tool for gait analysis in the healthy and pathological population. The first-generation smart insole PODOSmart® system was first introduced in 2019 as a new tool for gait analysis against high-cost ...
Matthew Beckman, Ph.D., Director of Laboratory Services at GENETWORx said, “The staff at GENETWORx has been very pleased with the performance of the BioGX Xfree COVID-19 test. ...
The test arrived in the mail in early November. I took it on a Wednesday, then mailed off my sample to Vienna for processing. On Friday, I received an email with a link to my results: negative. I didn’t have the symptoms anyway, apart from fatigue—a common symptom of having an early rising toddler—but given the fact that many carriers remain asymptomatic, it was good to confirm ...
Gauss Surgical, a health technology company, announced that a new study published in the International Journal of Obstetric Anesthesia concluded that the use of the company’s Triton system to monitor maternal blood loss during labor and delivery was associated with earlier postpartum hemorrhage intervention and cost savings. Researchers at Mount Sinai Hospital (New York, ...
While there is a significant financial investment in the acquisition of Dynamic Navigation hardware and software, the extrapolation of the costs over time diminishes in contrast to the increasing costs of the manufacture of static guides. CBCT acquisition and virtual planning are done at the same appointment unlike static guides which require multiple ...
ByClaroNav
"Both of these new products will help researchers achieve faster, more reliable separations, lowering their cost per analysis," said Helen Stimson, Agilent vice president and general manager of the Chemistries and Supplies Division. ...